Drugs / DER 45 EV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00940992 | Jan → Sep 2012 | rosacea | Sol-Gel Technologies, Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DER 45 EV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00940992 ↗ |
| Route | Topical | “Topical application to face for 12 weeks” NCT00940992 ↗ |